Skip to content

ROIV

Roivant Sciences Ltd.

NASDAQ · GBHealthcareBiotechnology
$34.47-0.12%

Price as of Jul 20, 2026

ROIV ownership

Roivant Sciences Ltd. ownership & insider activity

Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.

Insider Activity

Sentiment
0/100
Buys (3m)
0
Sells (3m)
24
Net (3m)
-$193.1M
Insider trades by month Buys Sells
Feb
Mar
Apr
May
Jun
Jul
Context3-month price +26.7%Institutions accumulating (13F)
DateInsiderTypeSharesPrice
Jul 2, 2026Fitzgerald MeghandirectorSell10,000$34.90
Jul 2, 2026Fitzgerald MeghandirectorOption10,000$8.80
Jul 2, 2026Gline Matthewdirector, officer: CEOTax76,171$35.39
Jul 2, 2026Torti Frankofficer: President and Vant ChairTax40,310$35.39
Jul 2, 2026Sukhatme Mayukhdirector, officer: President & CIOTax46,878$35.39
Jul 1, 2026Epperly Melissa B,directorSell2,748$34.71
Jul 1, 2026Epperly Melissa B,directorOption17,750$4.46
Jul 1, 2026Epperly Melissa B,directorSell15,002$34.32
Jun 30, 2026MANCHESTER KEITH SdirectorSell12,380$35.28
Jun 30, 2026QVT Financial LPother: Director by DeputizationSell12,380$35.28
Jun 30, 2026QVT Financial LPother: Director by DeputizationSell600,000$34.59
Jun 30, 2026MANCHESTER KEITH SdirectorSell200,000$34.44
Jun 30, 2026QVT Financial LPother: Director by DeputizationSell200,000$34.44
Jun 30, 2026QVT Financial LPother: Director by DeputizationSell300,783$33.92
Jun 30, 2026Gold Daniel AllendirectorSell300,783$33.92
Jun 30, 2026Gold Daniel AllendirectorSell200,000$34.44
Jun 30, 2026MANCHESTER KEITH SdirectorSell325,000$34.07
Jun 30, 2026Gold Daniel AllendirectorSell325,000$34.07
Jun 30, 2026MANCHESTER KEITH SdirectorSell600,000$34.59
Jun 30, 2026QVT Financial LPother: Director by DeputizationSell325,000$34.07
Jun 30, 2026Gold Daniel AllendirectorSell12,380$35.28
Jun 30, 2026MANCHESTER KEITH SdirectorSell300,783$33.92
Jun 30, 2026Gold Daniel AllendirectorSell600,000$34.59
Jun 29, 2026Sukhatme Mayukhdirector, officer: President & CIOSell500,000$34.13
Jun 29, 2026Sukhatme Mayukhdirector, officer: President & CIOOption500,000$3.85
Jun 26, 2026Venker Ericofficer: President & Immunovant CEOSell153,766$33.05
Jun 26, 2026Venker Ericofficer: President & Immunovant CEOSell46,234$33.51
Jun 26, 2026Venker Ericofficer: President & Immunovant CEOOption200,000$3.85
Jun 23, 2026Pulik Richardofficer: CFOTax2,129$31.43
Jun 23, 2026Humes Jenniferofficer: Chief Accounting OfficerTax3,582$31.43

Source: ROIV SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.

Institutional activity (13F)

How institutions changed their ROIV positions over the last 6 months (SEC Form 13F).

Increased
333
New positions
191
Reduced
236
Sold out
91
Largest moves
InstitutionActionSharesFiled
FMR LLCIncreased78.0MMay 15, 2026
FMR LLCIncreased65.8MFeb 17, 2026
MORGAN STANLEYIncreased58.4MFeb 13, 2026
MORGAN STANLEYReduced51.8MMay 15, 2026
BLACKROCK, INC.Increased44.3MMay 13, 2026
VANGUARD GROUP INCIncreased42.1MJan 29, 2026
BLACKROCK, INC.Increased41.2MFeb 12, 2026
QVT FINANCIAL LPReduced26.4MFeb 13, 2026
QVT FINANCIAL LPReduced25.2MMay 15, 2026
UBS GROUP AGIncreased22.6MMay 5, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position20.7MMay 15, 2026
VANGUARD PORTFOLIO MANAGEMENT LLCNew Position19.8MMay 8, 2026
UBS GROUP AGIncreased18.4MJan 29, 2026
STATE STREET CORPReduced17.4MFeb 13, 2026
SB INVESTMENT ADVISERS (UK) LTDReduced16.4MFeb 18, 2026

Source: SEC Form 13F filings. For informational purposes only — not investment advice.